A Double-blind, Randomised, Placebo-controlled, Crossover Study to Assess the Efficacy of XEN-D0501, a Transient Receptor Potential Vanilloid Receptor 1 (TRPV1) Antagonist, in Reducing the Frequency of Cough in Patients With Chronic Idiopathic Cough.
Phase of Trial: Phase II
Latest Information Update: 24 May 2017
Price : $35 *
At a glance
- Drugs XEN D0501 (Primary)
- Indications Cough
- Focus Therapeutic Use
- Sponsors Xention
- 24 May 2017 Primary endpoint (Change from baseline after 14-days treatment in objective daytime cough frequency on XEN-D0501 compared to placebo) has not been met, according to the results presented at the 113th International Conference of the American Thoracic Society
- 24 May 2017 Results assessing efficacy of XEN-D0501 in pre-clinical and clinical capsaicin cough challenge studies, presented at the 113th International Conference of the American Thoracic Society
- 14 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.